Does the media favor ELVN or ESPR?

In the previous week, Enliven Therapeutics had 7 more articles in the media than Esperion Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 1 mentions for Esperion Therapeutics. Enliven Therapeutics' average media sentiment score of 0.80 beat Esperion Therapeutics' score of 0.51 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ESPR or IDYA?

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Esperion Therapeutics. MarketBeat recorded 6 mentions for IDEAYA Biosciences and 1 mentions for Esperion Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.77 beat Esperion Therapeutics' score of 0.51 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MBX or ESPR?

In the previous week, MBX Biosciences had 2 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.51 beat MBX Biosciences' score of -0.19 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRON or ESPR?

In the previous week, Disc Medicine had 3 more articles in the media than Esperion Therapeutics. MarketBeat recorded 4 mentions for Disc Medicine and 1 mentions for Esperion Therapeutics. Disc Medicine's average media sentiment score of 0.62 beat Esperion Therapeutics' score of 0.51 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ESPR or RARE?

In the previous week, Esperion Therapeutics and Esperion Therapeutics both had 1 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 0.80 beat Esperion Therapeutics' score of 0.51 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Esperion Therapeutics (ESPR) Competitors

$3.18 0.00 (0.00%)

As of 07/13/2026

Compare

ESPR vs. ELVN, IDYA, MBX, IRON, and RARE

Should you buy Esperion Therapeutics stock or one of its competitors? MarketBeat compares Esperion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Esperion Therapeutics include Enliven Therapeutics (ELVN), IDEAYA Biosciences (IDYA), MBX Biosciences (MBX), Disc Medicine (IRON), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.

How does Esperion Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Enliven Therapeutics presently has a consensus target price of $70.50, suggesting a potential upside of 33.40%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enliven Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

In the previous week, Enliven Therapeutics had 7 more articles in the media than Esperion Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 1 mentions for Esperion Therapeutics. Enliven Therapeutics' average media sentiment score of 0.80 beat Esperion Therapeutics' score of 0.51 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher revenue and earnings than Enliven Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Esperion Therapeutics has a net margin of 0.12% compared to Enliven Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Enliven Therapeutics and Esperion Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to IDEAYA Biosciences?

Esperion Therapeutics (NASDAQ:ESPR) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 74.21%. IDEAYA Biosciences has a consensus target price of $50.25, indicating a potential upside of 43.57%. Given Esperion Therapeutics' higher probable upside, equities analysts plainly believe Esperion Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Esperion Therapeutics has a net margin of 0.12% compared to IDEAYA Biosciences' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Esperion Therapeutics. MarketBeat recorded 6 mentions for IDEAYA Biosciences and 1 mentions for Esperion Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.77 beat Esperion Therapeutics' score of 0.51 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher revenue and earnings than IDEAYA Biosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
IDEAYA Biosciences	$218.71M	14.06	-$113.70M	-$1.60	N/A

Summary

Esperion Therapeutics and IDEAYA Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Esperion Therapeutics (NASDAQ:ESPR) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

47.4% of Esperion Therapeutics shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Esperion Therapeutics has a net margin of 0.12% compared to MBX Biosciences' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Esperion Therapeutics	0.12%	-0.14%	0.12%

In the previous week, MBX Biosciences had 2 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for MBX Biosciences and 1 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.51 beat MBX Biosciences' score of -0.19 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher revenue and earnings than MBX Biosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

MBX Biosciences has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

MBX Biosciences currently has a consensus price target of $63.00, indicating a potential upside of 8.06%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 74.21%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Disc Medicine has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Disc Medicine's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Esperion Therapeutics	0.12%	-0.14%	0.12%

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Disc Medicine had 3 more articles in the media than Esperion Therapeutics. MarketBeat recorded 4 mentions for Disc Medicine and 1 mentions for Esperion Therapeutics. Disc Medicine's average media sentiment score of 0.62 beat Esperion Therapeutics' score of 0.51 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher revenue and earnings than Disc Medicine. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Disc Medicine currently has a consensus target price of $104.44, suggesting a potential upside of 40.53%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Esperion Therapeutics compare to Ultragenyx Pharmaceutical?

Esperion Therapeutics (NASDAQ:ESPR) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Esperion Therapeutics presently has a consensus target price of $5.54, suggesting a potential upside of 74.21%. Ultragenyx Pharmaceutical has a consensus target price of $58.41, suggesting a potential upside of 111.25%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Esperion Therapeutics has a net margin of 0.12% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Esperion Therapeutics' return on equity of -0.14% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Esperion Therapeutics and Esperion Therapeutics both had 1 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 0.80 beat Esperion Therapeutics' score of 0.51 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Ultragenyx Pharmaceutical	$673M	4.05	-$575M	-$6.11	N/A

Summary

Ultragenyx Pharmaceutical beats Esperion Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Esperion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESPR vs. The Competition

Export

Metric	Esperion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$819.45M	$3.10B	$7.01B	$12.68B
Dividend Yield	N/A	2.04%	2.67%	9.42%
P/E Ratio	-53.00	19.82	26.82	23.95
Price / Sales	2.03	785.64	576.32	115.11
Price / Cash	N/A	28.08	50.60	60.45
Price / Book	-2.52	4.21	10.52	6.16
Net Income	-$22.68M	$65.94M	$3.60B	$331.73M
7 Day Performance	N/A	-1.48%	-1.34%	-0.92%
1 Month Performance	0.63%	-1.92%	-0.29%	-2.23%
1 Year Performance	139.10%	10.99%	18.96%	14.79%

Esperion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESPR Esperion Therapeutics	2.8668 of 5 stars	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200
ELVN Enliven Therapeutics	3.3607 of 5 stars	$51.67 -2.9%	$69.17 +33.9%	+145.1%	$3.24B	N/A	N/A	50	News Coverage Analyst Forecast
IDYA IDEAYA Biosciences	3.8808 of 5 stars	$35.45 -1.6%	$50.25 +41.7%	+58.9%	$3.16B	$218.71M	N/A	80
MBX MBX Biosciences	1.2583 of 5 stars	$60.14 -4.4%	$63.00 +4.8%	N/A	$2.99B	N/A	N/A	N/A	Analyst Downgrade
IRON Disc Medicine	2.3707 of 5 stars	$74.38 -2.3%	$104.44 +40.4%	+22.4%	$2.91B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESPR) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Esperion Therapeutics (ESPR) Competitors

ESPR vs. ELVN, IDYA, MBX, IRON, and RARE

How does Esperion Therapeutics compare to Enliven Therapeutics?

Summary

How does Esperion Therapeutics compare to IDEAYA Biosciences?

Summary

How does Esperion Therapeutics compare to MBX Biosciences?

Summary

How does Esperion Therapeutics compare to Disc Medicine?

Summary

How does Esperion Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Esperion Therapeutics (ESPR) Competitors

ESPR vs. ELVN, IDYA, MBX, IRON, and RARE

How does Esperion Therapeutics compare to Enliven Therapeutics?

Do analysts recommend ELVN or ESPR?

Which has more volatility and risk, ELVN or ESPR?

Does the media favor ELVN or ESPR?

Which has higher valuation & earnings, ELVN or ESPR?

Do insiders & institutionals have more ownership in ELVN or ESPR?

Is ELVN or ESPR more profitable?

Summary

How does Esperion Therapeutics compare to IDEAYA Biosciences?

Do insiders and institutionals believe in ESPR or IDYA?

Do analysts rate ESPR or IDYA?

Is ESPR or IDYA more profitable?

Which has more volatility and risk, ESPR or IDYA?

Does the media refer more to ESPR or IDYA?

Which has stronger valuation and earnings, ESPR or IDYA?

Summary

How does Esperion Therapeutics compare to MBX Biosciences?

Do insiders & institutionals hold more shares of MBX or ESPR?

Is MBX or ESPR more profitable?

Does the media prefer MBX or ESPR?

Which has stronger valuation and earnings, MBX or ESPR?

Which has more volatility & risk, MBX or ESPR?

Do analysts rate MBX or ESPR?

Summary

How does Esperion Therapeutics compare to Disc Medicine?

Which has more risk & volatility, IRON or ESPR?

Is IRON or ESPR more profitable?

Do insiders & institutionals have more ownership in IRON or ESPR?

Does the media favor IRON or ESPR?

Which has higher earnings & valuation, IRON or ESPR?

Do analysts rate IRON or ESPR?

Summary

How does Esperion Therapeutics compare to Ultragenyx Pharmaceutical?

Do institutionals & insiders have more ownership in ESPR or RARE?

Which has more volatility & risk, ESPR or RARE?

Do analysts prefer ESPR or RARE?

Is ESPR or RARE more profitable?

Does the media refer more to ESPR or RARE?

Which has higher valuation & earnings, ESPR or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools